Trader makes bullish bet on Sage Therapeutics
Option traders are making a bet on a rise in shares of Sage Therapeutics (SAGE) Monday. A single lot of 2,472 contracts of the June 100 call crossed the tape at a little after noon ET today. Previous open interest at the strike was zero, and these contracts moved on the high side of a relatively wide bid-ask spread, indicating that this trade shows new position being opened.
Already a member?
Login to see your Unusual Options Activity Trade Idea.
Not yet a member?
You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.
Become A Member
About Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.